Which medication may enhance the risk of hypokalemia when used with non-potassium sparing diuretics?

The medication that may enhance the risk of hypokalemia when used with non-potassium sparing diuretics is Qsymia. Qsymia is a combination of phentermine and topiramate, and it is important to understand how this combination can interact with diuretics.

Phentermine, a stimulant that promotes weight loss, can cause changes in fluid balance, and topiramate is known to have diuretic-like effects that may lead to increased urinary excretion of potassium. When Qsymia is used alongside non-potassium sparing diuretics, which already promote potassium loss through increased urine output, this can significantly amplify the risk of developing hypokalemia, a condition characterized by low potassium levels in the bloodstream.

The other medications listed have different mechanisms of action and do not carry the same risk when combined with diuretics. For example, liraglutide is a GLP-1 receptor agonist that mainly affects glucose metabolism and does not have a significant diuretic effect. Orlistat works by inhibiting fat absorption in the intestine and does not influence potassium levels in the body. Therefore, while the other medications may have their own side effects and interactions, Qsymia presents a unique risk of hypokalemia